
In an NIH-sponsored clinical study of 110 CF patients with exocrine pancreatic insufficiency (EPI), Encala1,2
- Increased the coefficient of fat absorption (CFA) by a mean of 6% (82% to 88%) over 3 months and demonstrated improvement in blood levels for essential fatty acids, vitamins A and K, and choline2
- Elevated CFA 8% over baseline at 3 months among patients with a mean baseline of 77% CFA
- Increased weight, height, and BMI in only 3 months, versus no change in the group taking an active placebo (a calorically similar supplement used for comparison)